Veterinary Vaccines Market at US$ 6,100 Mn in 2017. This is projected to reach US$ 12,000 Mn by 2026

Veterinary vaccines are increasingly becoming integral to comprehensive control strategies to prevent and eradicate several diseases of the livestock. A classic case in point is the leveraging veterinary vaccines as a part of such a control strategy to eradicate Rinderpest through vaccination

Developers of veterinary vaccines have made astounding progress in understanding the transmission risk profiles of target host species in guiding their R&D efforts. Equally importantly, the growth trajectories of veterinary vaccines market around the world have been dictated by the propositions of cost and safety, in addition to efficacy of the products. Thus, the direction of development of the vaccine toward a specific animal type depends on the troika of cost, safety, and efficacy. The global veterinary vaccines market was pegged at US$ 6,100 Mn in 2017. This is projected to reach US$ 12,000 Mn by 2026 by advancing at a CAGR of above 6.5% during the forecast period of 2018 to 2026.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111985

Economic Burden of The Infection Diseases of Livestock Animals Key Driver

The economic burden of a certain disease is unarguably a major consideration for investors and public research organizations holding stakes in the veterinary vaccines market. Considerable morbidity and mortality of the infection diseases of the livestock is a key driver. The growing demand for vaccines for non-infectious diseases notably including allergies and cancers has also imparted momentum to the strides in the veterinary vaccines market. Another major stimulant for R&D in the veterinary vaccines market are the pressing need to protect humans from zoonoses. In the recent months of the emerging COVID-19 pandemic, this has gained groundswell of attention. Classic case in point is development and application of vaccination for domestic dogs to protect humans against rabies.

The key technologies being marketed to customers in the veterinary vaccines market are activated vaccines, conjugate vaccines, live attenuated vaccines, and toxoid vaccines. Each of these constitute a different approach and hence have strengths and limitations to meet the stated objectives. For instance, the steady demand for booster immunizations inactivated whole-pathogen vaccines has propelled the revenue sales in the veterinary vaccines market.

Live attenuated vaccines and DNA vaccines have emerged as highly lucrative segments. Live attenuated vaccines have been contributing a major share of the veterinary vaccines market in recent years. Key advantages have circumscribed the tailwinds associated with the segment, namely, their ability to express wider range of relevant pathogen antigens, the effectiveness of these without the need for adjuvant, and their purported efficacy against protozoan or helminth parasites. A case in point is the gush of R&D spending by players in the veterinary vaccines market on the development of BCG vaccine against bovine TB. Players in the veterinary vaccines market intend to reap vast revenue gains from R&D in live attenuated vaccines and DNA vaccines.

View full report@ https://qyresearchmedical.com/report/veterinary-vaccines-market-technology-inactivated-vaccines-conjugate-vaccines-live-attenuated-vaccines-toxoid-vaccines-animal-type-livestock-animal-vaccines-companion-animal-vaccines-global-industry-ana-018-2030/111985

Of special interest in vaccine technologies are DNA vaccines. Both technical superiority and macro-economic factors has reinforced the prospects of DNA vaccines in the overall veterinary vaccines market. Their ease of designing and their cost effectiveness for customers are the favorable economic propositions propelling the popularity of veterinary vaccines. Additionally, they ca induce both cellular and humoral immune responses.

The study on the veterinary vaccines market has found that the segment is poised for significant growth during the forecast period. Clinically, researchers have found DNA vaccines to be effective against multiple pathogens for poultry industry through simultaneous immunizations. DNA vaccines have been successful against West Nile virus in horses and canine melanoma in dog, and many more. These applications paint a positive outlook of the DNA vaccines segment in the veterinary vaccines market.

However, DNA vaccines are not applicable for mass vaccinations, perhaps due to lack of studies on these. The growing commercial production of DNA vaccines has spurred revenue sales for vaccine manufacturing companies. The salient advantages they possess over conventional vaccines have attracted regulators to approve their use in certain diseases. A case in point is approval of highly pathogenic H5 avian influenza by the United States Department of Agriculture (USDA).

Extensive efforts of improving the immunogenicity of DNA vaccines are propelling the opportunities in the global veterinary vaccines market. As a key approach to this end, researchers continue to look ways for optimizing the antigens that are carried in plasmids. Nevertheless, there exits an unmet need in the lack of widespread utilization of DNA vaccines in poultry. Another area where vaccine developers of DNA veterinary vaccines are working is optimizing the routes of administration.

A number of novel delivery methods and routes have enriched the value chain of DNA vaccines pipeline in the veterinary vaccines market. In this regard, oral administration is gaining preference over parenteral routes in poultry. Advancements in expression vectors have enabled veterinary vaccine manufacturers to overcome the key obstacles in DNA vaccines. Several approaches have been used for enhancing the expression in newly developed DNA vaccines. A case in point is focus on improving the antibody response in chickens.

In recent years, gram-negative bacteria have been considered as potential carriers for DNA vaccines. Broadly, extracellular pathogens, intraphagosomal bacteria, and intracytosolic bacteria have attracted R&D, thus boosting the veterinary vaccines market. Advancements in attenuation methods have also enables vaccine manufacturers to strengthen their product profiles in recent years.

North America Lucrative Market

Geographically, the study segments the veterinary vaccines market into North America, Latin America, the Middle East and Africa, Asia Pacific, and Europe. Of these, North America held a major share of the global market in 2017. The presence of a robust vaccination programs for livestock and domesticated animals, coupled with rise in ownership of companion animals, have fueled the revenue prospects of the North America veterinary vaccines market.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111985/2900

On the other hand, Asia Pacific is an emerging market, and is projected to witness opportunities rise at significant pace during the forecast period. Meanwhile, Latin America and Middle East & Africa are anticipated to witness several lucrative avenues. Growing concern of zoonotic diseases and growing government spending on immunization programs for poultry are the ke drivers for growth.

The global veterinary vaccines market has been segmented as follows:

Technology

  • Inactivated Vaccines
  • Conjugate Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Other Vaccines

Animal

  • Livestock Animal Vaccines
  • Companion Animal Vaccines

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Veterinary Vaccines Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Veterinary Vaccines Market Analysis and Forecasts, 2016–2026
4.3.1. Market Revenue Projection (US$ Mn)

Chapter 5. Market Outlook
5.1. White Space Analysis
5.2. Disease Outbreak Globally : Livestock Animal Disease
5.3. Main (Vector Borne Disease) VBDs affecting livestock
5.4. Animal Population (Mn), by Key Country in 2017
5.5. Top Ten Countries with Highest Number of Vets and Vet Clinics, 2016
5.6. Pet Ownership (%) by Key Country, 2016
5.7. Key Merger & Acquisition in Animal Health Industry
5.8. Regulatory Scenario by Region

Chapter 6. Global Veterinary Vaccines Market Analysis and Forecasts, by Technology
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Technology, 2017–2026
6.3.1. Inactivated Vaccines
6.3.2. Conjugate Vaccines
6.3.3. Live Attenuated Vaccines
6.3.4. Toxoid Vaccines
6.3.5. Other Vaccines
6.4. Market Attractiveness, by Technology

Chapter 7. Global Veterinary Vaccines Market Analysis and Forecasts, by Animal
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Animal, 2017–2026
7.3.1. Livestock Animal Vaccines
7.3.2. Companion Animal Vaccines
7.4. Market Attractiveness, by Animal

Chapter 8. Global Veterinary Vaccines Market Analysis and Forecasts, by Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Veterinary Vaccines Market Analysis and Forecast
9.1. Market Value Forecast, by Country, 2017–2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Share Analysis, by Technology, 2017–2026
9.3. Market Value Forecast, by Technology, 2016–2026
9.3.1. Inactivated Vaccines
9.3.2. Conjugate Vaccines
9.3.3. Live Attenuated Vaccines
9.3.4. Toxoid Vaccines
9.3.5. Other Vaccines
9.4. Market Value Share Analysis, by Animal, 2017–2026
9.5. Market Value Forecast, by Animal, 2016–2026
9.5.1. Livestock Animal Vaccines
9.5.2. Companion Animal Vaccines
9.6. Market Attractiveness Analysis
9.6.1. By Country
9.6.2. By Technology
9.6.3. By Animal

Chapter 10. Europe Veterinary Vaccines Market Analysis and Forecast
10.1. Market Value Forecast, by Country/Sub-region, 2017–2026
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Technology, 2017–2026
10.3. Market Value Forecast, by Technology, 2016–2026
10.3.1. Inactivated Vaccines
10.3.2. Conjugate Vaccines
10.3.3. Live Attenuated Vaccines
10.3.4. Toxoid Vaccines
10.3.5. Other Vaccines
10.4. Market Value Share Analysis, by Animal, 2017–2026
10.5. Market Value Forecast, by Animal, 2016–2026
10.5.1. Livestock Animal Vaccines
10.5.2. Companion Animal Vaccines
10.6. Market Attractiveness Analysis
10.6.1. By Country/Sub-region
10.6.2. By Technology
10.6.3. By Animal

Chapter 11. Asia Pacific Veterinary Vaccines Market Analysis and Forecast
11.1. Market Value Forecast, by Country/Sub-region, 2017–2026
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of Asia Pacific
11.2. Market Value Share Analysis, by Technology, 2017–2026
11.3. Market Value Forecast, by Technology, 2016–2026
11.3.1. Inactivated Vaccines
11.3.2. Conjugate Vaccines
11.3.3. Live Attenuated Vaccines
11.3.4. Toxoid Vaccines
11.3.5. Other Vaccines
11.4. Market Value Share Analysis, by Animal, 2017–2026
11.5. Market Value Forecast, by Animal, 2016–2026
11.5.1. Livestock Animal Vaccines
11.5.2. Companion Animal Vaccines
11.6. Market Attractiveness Analysis
11.6.1. By Country/Sub-region
11.6.2. By Technology
11.6.3. By Animal

Chapter 12. Latin America Veterinary Vaccines Market Analysis and Forecast
12.1. Market Value Forecast, by Country/Sub-region, 2017–2026
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of Latin America
12.2. Market Value Share Analysis, by Technology, 2017–2026
12.3. Market Value Forecast, by Technology, 2016–2026
12.3.1. Inactivated Vaccines
12.3.2. Conjugate Vaccines
12.3.3. Live Attenuated Vaccines
12.3.4. Toxoid Vaccines
12.3.5. Other Vaccines
12.4. Market Value Share Analysis, by Animal, 2017–2026
12.5. Market Value Forecast, by Animal, 2016–2026
12.5.1. Livestock Animal Vaccines
12.5.2. Companion Animal Vaccines
12.6. Market Attractiveness Analysis
12.6.1. By Country/Sub-region
12.6.2. By Technology
12.6.3. By Animal

Chapter 13. Middle East and Africa Veterinary Vaccines Market Analysis and Forecast
13.1. Market Value Forecast, by Country/Sub-region, 2017–2026
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Technology, 2017–2026
13.3. Market Value Forecast, by Technology, 2016–2026
13.3.1. Inactivated Vaccines
13.3.2. Conjugate Vaccines
13.3.3. Live Attenuated Vaccines
13.3.4. Toxoid Vaccines
13.3.5. Other Vaccines
13.4. Market Value Share Analysis, by Animal, 2017–2026
13.5. Market Value Forecast, by Animal, 2016–2026
13.5.1. Livestock Animal Vaccines
13.5.2. Companion Animal Vaccines
13.6. Market Attractiveness Analysis
13.6.1. By Country/Sub-region
13.6.2. By Technology
13.6.3. By Animal

Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Eli Lilly and Company
14.1.2. Boehringer Ingelheim GmbH
14.1.3. Merck Animal Health
14.1.4. Virbac
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. Boehringer Ingelheim GmbH (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. Merck Animal Health (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Zoetis Inc.  (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Eli Lilly and Company (Elanco Animal Health) (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Bayer AG (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. Ceva Santé Animale. (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. Virbac (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Biovac (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. Neogen Corporation (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Immucell Corporation (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111985/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi